Quantbot Technologies LP Acquires New Holdings in Kenvue Inc. $KVUE

Quantbot Technologies LP bought a new stake in Kenvue Inc. (NYSE:KVUE) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 88,898 shares of the company’s stock, valued at approximately $1,699,000.

Several other hedge funds also recently bought and sold shares of the stock. Varma Mutual Pension Insurance Co acquired a new stake in shares of Kenvue during the second quarter valued at about $9,263,000. Westpac Banking Corp acquired a new position in shares of Kenvue in the 2nd quarter worth approximately $747,000. Korea Investment CORP purchased a new position in shares of Kenvue during the 2nd quarter worth approximately $25,931,000. EP Wealth Advisors LLC purchased a new position in shares of Kenvue during the 2nd quarter worth approximately $272,000. Finally, Heartland Bank & Trust Co purchased a new position in shares of Kenvue during the 2nd quarter worth approximately $231,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $19.41 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $21.63. The stock has a market capitalization of $37.27 billion, a PE ratio of 22.30, a P/E/G ratio of 1.36 and a beta of 0.47. The firm has a 50 day moving average of $19.08 and a two-hundred day moving average of $18.21.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same quarter last year, the firm earned $0.29 EPS. The business’s revenue was up 3.0% on a year-over-year basis. On average, research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Wednesday, August 12th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is presently 96.55%.

Analyst Ratings Changes

KVUE has been the topic of a number of research analyst reports. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Barclays raised their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group cut their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Finally, Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.